|
Quantitative data mining for drug-adverse event safety signal detection using MEDLINE
|
Research Initiative
|
FDA
|
NLM
|
The objective of this initiative between NLM''s Cognitive Science Branch and the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) is to develop a mutually beneficial automated data mining analytical tool in which NLM’s electronic databases and resources (including MEDLINE) are utilized to support the FDA’s mission related to enhancing postmarket drug safety surveillance and safe use.
|
|
RABRAT (Radiobiology Bioterrorism Research and Training Group)
|
Meeting/ Workshop
|
FDA, OS
|
NCI
|
Monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications and other events and information related to preparing the U.S. Government to respond to nuclear terrorism.
|
|
Racial and Ethnic Approaches to Community Health Across the U. S. (REACH US)
|
Research Initiative
|
CDC
|
NIMHD
|
The purpose of the Racial and Ethical Approaches to Community Health Across the US (REACH U.S.) Program is for organizations serving racial and ethnic minority populations at increased risk for infant mortality, diabetes, cardiovascular diseases, Asthma, Hepatitis B, deficits in breast and cervical screening and management, deficits in child and/or adult immunization rates to develop, implement, and evaluate innovative community level intervention demonstrations which could be effective in eliminating health disparities. The racial and ethnic groups targeted by REACH U.S. include: African-Americans, Asian-Americans, Hawaiian Pacific Islanders, Hispanic-Americans, and American Indians or Alaskan Native populations.
|
|
Racial disparities in prostate cancer incidence rates by census division in the United States, 1999-2008
|
Research Initiative
|
CDC
|
NCI
|
An analysis of the National Program of Cancer Registries database to assess census division differences by race (white, black) in trends of prostate cancer.
|
|
Radiation Emergency Medical Management (REMM)
|
Resource Development
|
CDC, OS
|
NLM, NCI
|
This activity is to develop a comprehensive web resource. Radiation Emergency Medical Management (REMM) is a mechanism to collect, evaluate, collate, store and make available electronically to health care professionals immediate, up-to-date, evidence-based clinical information they would use to treat civilian patients and others affected by radiation incidents.
|
|
Radiation Exposure Screening and Education Program (RESEP)
|
Meeting/ Workshop
|
HRSA
|
NCI
|
NCI participated in the Radiation Exposure Screening and Education Program (RESEP) workshop (Rockville, MD Sept. 11-13, 2012) and delivered a presentation on “Exposure to Iodine-131 from Nuclear Weapons Tests and the Risk of Thyroid Cancer and Other Diseases".
|
|
Radiation/Nuclear Biodosimetry Team
|
Meeting/ Workshop
|
OS
|
NIAID
|
no description provided
|
|
Radiation/Nuclear Integrated Project Team
|
Meeting/ Workshop
|
OS
|
NIAID
|
NIAID participates on the Integrated Project Team for Radiation/Nuclear Radiation Nuclear topics to provide subject matter expertise, advice, and guidance on medical countermeasure development, requirements, and preparedness/response.
|
|
Radiation/Nuclear Technical Evaluation Review Panel
|
Meeting/ Workshop
|
OS
|
NIAID
|
NIAID participates on the Radiation/Nuclear Technical Evaluation Review Panel to review white papers and proposals received by HHS/Biomedical Advanced Research and Development Authority (BARDA) for the development of radiation nuclear medical countermeasures. NIAID provides scientific and programmatic critiques and reviews of selected submissions.
|
|
Randomized Intervention in Children with Vesicoureteral Reflux (RIVUR)
|
Research Initiative
|
OS
|
NIDDK
|
The multicenter, randomized, double-blind, placebo-controlled RIVUR trial is designed to determine whether daily antimicrobial prophylaxis is superior to placebo in preventing recurrence of UTI in children with VUR. The study is designed to recruit 600 children (approximately 300 in each treatment group) over an 18-24 month period. The primary endpoint is recurrence of UTI. Quality of life, compliance, safety parameters, utilization of health resources, and change in VUR will be assessed periodically throughout the study.
|